Skip to main content

Though Illumina s Q2 Revenues Increase 38 Percent, Stock Drops 14.7 Percent

NEW YORK, July 27 (GenomeWeb News) - Illumina yesterday reported increased revenues and losses for the second quarter of 2005.

 

The increased loss caused shares in the San Diego SNP-genotyping company to fall 14.68 percent, or $1.91, to $11.10 during mid-afternoon trading.

 

Revenues totaled $15.8 million for the quarter, a 38-percent increase over last year's $11.5 million for the same period.

 

The company's research and development expenses climbed to $7.3 million, up from $5.3 million during the year-ago period.

 

Illumina's net loss amounted to $18.5 million, or $.46 per share, up from $3.5 million, or $.10 per share, during last year's second quarter. This included a $15.8 million write-off of in-process research and development that Illlumina acquired with CyVera in April.

 

As of July 3, Illumina had $54.6 million in cash and investments.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.